Journal Mobile Options
Table of Contents
Vol. 12, No. 2, 2006
Issue release date: March 2006
Eur Addict Res 2006;12:74–82
(DOI:10.1159/000090426)

Determinants of Health-Related Quality of Life of Opiate Users at Entry to Low-Threshold Methadone Programs

Millson P. · Challacombe L. · Villeneuve P.J. · Strike C.J. · Fischer B. · Myers T. · Shore R. · Hopkins S.
aDepartment of Public Health Sciences, bHIV Studies Unit, and cDepartment of Criminology, University of Toronto; dHealth Canada, Ottawa; eCentre for Addiction and Mental Health, Toronto; fStreet Health Centre, Kingston; gKFL&A Health Unit, Kingston; hThe Works, and iToronto Department of Public Health, Toronto, Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: The aim of this study was to conduct an exploratory analysis of factors associated with poor health-related quality of life (HRQOL) among opiate users at entry to low-threshold methadone treatment. Methods: The SF-36 questionnaire was administered to 145 opiate users at enrollment into low-threshold methadone maintenance programs. ANOVA and correlational analyses were performed to investigate the determinants of poor physical and mental composite summary scales (PCS and MCS) of the SF-36 among opiate users. Stepwise regression methods were also employed to fit PCS and MCS multivariate models. Results: Age, employment status, chronic medical conditions, hospitalization, emotional abuse, sexual abuse and age at first injection episode were significantly associated with PCS. Mental health problems, sexual abuse, physical abuse, the use of sedatives, the use of cocaine, the number of days of cocaine use, sedative use and multiple substance use in the past month were significantly associated with MCS. The variances in the MCS and PCS were not readily explained by any one factor. Conclusion: The multiplicity of factors influencing HRQOL of opiate users suggests the need for a range of services within the context of a methadone program, addressing primary medical care needs as well as treatment for both mental health problems and abuse issues.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Talley NJ, Wiklund I: Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures. Qual Life Res 2005;14:21–33.
  2. Robinson FP: Measurement of quality of life in HIV disease. J Assoc Nurses AIDS Care 2004;15(suppl):14S–19S.

    External Resources

  3. Talley NJ, Wiklund I: Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures. Qual Life Res 2005;14:21–33.
  4. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F: Impact of hepatitis C on health-related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790–800.
  5. Schlenk EA, Erlen JA, Jacob-Dunbar J, et al: Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res 1998;7:57–65.
  6. Centres for Disease Control and Prevention: Measuring Healthy Days. Atlanta, CDC, 2000.
  7. Ryan CF, White JM: Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction 1996;91:39–45.
  8. Stein MD, Mulvey KP, Plough A, Samet JH: The functioning and well-being of persons who seek treatment for drug and alcohol use. J Subst Abuse 1998;10:75–84.
  9. Millson P, Challacombe L, Villeneuve PJ, Fischer B, Strike CJ, Myers T, Shore R, Hopkins S, Raftis S, Pearson M: Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health 2004;95:99–103.
  10. Finch E, Groves I, Feinmann C, Farmer R: A low threshold methadone stabilisation programme description and first stage evaluation. Addict Res 1995;3:63–71.

    External Resources

  11. Ryrie IW, Dickson J, Robbins C, Maclean K, Climpson C: Evaluation of a low-threshold clinic for opiate dependent drug users. J Psychiatr Ment Health Nurs 1997;4:105–110.
  12. Hartgers C, van den Hoek A, Krijnen P, Coutinho RA: HIV prevalence and risk behaviour among injecting drug users who participate in ‘low-threshold’ methadone programs in Amsterdam. Am J Public Health 1992;82:547–551.
  13. Van Ameijden EJ, Langendam MW, Coutinho RA: Dose-effect relationship between overdose mortality and prescribed methadone dosage in low threshold maintenance programs. Addict Behav 1999;24:559–563.
  14. Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 1992;30:473–483.
  15. Ware JE, Kosinski M, Keller SD: SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston, Health Assessment Lab, 1994.
  16. Birrell FN, Hassell AB, Jones PW, Dawes PT: How does the Short Form 36 Health Questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcomes measures and SF-36 population values? A cross-sectional study. Clin Rheumatol 2000;19:195–199.
  17. Heyland DK, Hopman W, Coo H, Tanmer J, McColl MA: Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000;28:3599–3605.
  18. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Mass PJ, Schroder FH: Health-related quality of life effects of radical prostatectomy and primary radiotherapy for screen detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001;19:1619–1628.
  19. Singer MA, Hopman WM, MacKenzie TA: Physical functioning and mental health in patients with chronic medical conditions. Qual Life Res 1999;8:687–691.
  20. Wiebe S, Matijevic S, Eliasziw M, Derry PA: Clinically important change in quality of life in epilepsy. J Neurol Neurosurg Psychiatry 2002;73:116–120.
  21. Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C, Joseph L, Brown JP, Murray TM, Adachi J, Hanley JD, Papadimitropoulos E and the Canadian Multicentre Osteoporosis Study Research Group: Canadian normative data for the SF-36 Health Survey. Can Med Assoc J 2000;163:265–271.
  22. Ware JE, Kosinski M, Bayliss MS, McHorney C, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Medical Care 1995:33:AS264–AS279.
  23. Strike CJ, Challacombe L, Myers T, Millson M: Needle exchange programs: delivery and access issues. Can J Public Health 2002:93:339–343.
  24. Anonymous: Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998;280:1936–1943.
  25. Brady KT, Lydiard RB, Malcolm R, Ballenger JC: Cocaine-induced psychosis. J Clin Psychiatry 1991:52:509–512.
  26. Khantzian EJ: Self-selection and progression in drug dependence. Psychiatry Digest 1975:10:19–22.
  27. Widom CS, Ames MA: Criminal consequences of childhood sexual victimization. Child Abuse Neglect 1994:18:303–318.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50